Gerresheimer (ETR:GXI) has been assigned a €66.00 ($78.57) price objective by equities research analysts at Deutsche Bank in a note issued to investors on Monday. The brokerage currently has a “neutral” rating on the stock. Deutsche Bank’s target price suggests a potential downside of 8.71% from the company’s previous close.
GXI has been the topic of several other research reports. JPMorgan Chase & Co. set a €87.70 ($104.40) target price on Gerresheimer and gave the company a “buy” rating in a report on Friday, December 29th. Berenberg Bank set a €75.00 ($89.29) target price on Gerresheimer and gave the company a “buy” rating in a report on Friday, December 8th. Commerzbank set a €77.00 ($91.67) target price on Gerresheimer and gave the company a “buy” rating in a report on Thursday, September 28th. Credit Suisse Group set a €80.00 ($95.24) target price on Gerresheimer and gave the company a “buy” rating in a report on Tuesday, October 10th. Finally, set a €65.00 ($77.38) target price on Gerresheimer and gave the company a “neutral” rating in a report on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of €71.20 ($84.76).
Gerresheimer (ETR:GXI) opened at €72.30 ($86.07) on Monday. Gerresheimer has a twelve month low of €59.97 ($71.39) and a twelve month high of €78.25 ($93.15). The firm has a market capitalization of $2,250.00 and a price-to-earnings ratio of 51.28.
ILLEGAL ACTIVITY NOTICE: “Gerresheimer (GXI) PT Set at €66.00 by Deutsche Bank” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/22/gerresheimer-gxi-pt-set-at-66-00-by-deutsche-bank.html.
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.